Last Updated : July 16, 2018
Details
FilesGeneric Name:
brodalumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Valeant Canada LP
Call for patient/clinician input open:
Brand Name:
Siliq
Project Line:
Reimbursement Review
Project Number:
SR0547-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Psoriasis, moderate to severe plaque
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 | |
|---|---|
| Call for patient input posted | November 08, 2017 |
| Patient group input closed | January 04, 2018 |
Clarification: - Patient input submission received | |
| Patient input summary sent for review to patient input groups | January 11, 2018 |
| Patient group comments on input summary closed | January 18, 2018 |
Clarification: - Patient input summary feedback received | |
| Submission received | December 14, 2017 |
| Submission accepted for review | January 05, 2018 |
| Review initiated | January 08, 2018 |
| Draft CDR review report(s) sent to applicant | March 22, 2018 |
| Comments from applicant on draft CDR review report(s) received | April 03, 2018 |
| Redaction requests from applicant on draft CDR review report(s) received | April 10, 2018 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | May 04, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | May 16, 2018 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | May 30, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | June 13, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | June 20, 2018 |
| CDEC Final Recommendation posted | June 22, 2018 |
| Final CDR review report(s) and patient input posted | July 16, 2018 |
Files
Last Updated : July 16, 2018